The current standard of care in glioblastoma management is surgery followed by chemotherapy and radiotherapy. Temozolomide is an alkylating agent most commonly used with a few other second line options. The efficacy of systemic chemotherapy in brain malignancies is limited due to the nature of the blood-brain barrier. Nanomedicine offers one avenue of improving drug delivery to these tumours in a more focussed and effective way in higher doses than currently possible, while simultaneously reducing systemic toxicity.
|Number of pages||1|
|Journal||JPMA. The Journal of the Pakistan Medical Association|
|Publication status||Published - 1 Nov 2021|
- Glioblastoma multiforme, brain tumour, nanotechnology